Sydney (Australia) – April 3, 2024. GlyTherix Ltd (GlyTherix) an Australian immuno-oncology company specialising in developing targeted radiotherapies for solid tumors today announces that Dr Colin Hayward has joined GlyTherix’s Clinical Advisory Board.
Based in North Carolina, USA Dr Hayward, was most recently the Chief Medical Officer of Telix Pharmaceuticals (ASX:TLX), a global specialty radiopharmaceutical company where he led Telix’s medical affairs and clinical development activities on a global basis. He has over 25 years of global pharmaceutical, biotechnology and drug development experience.
Colin has held a series of senior medical, executive and board-level roles with F. Hoffmann-La Roche, Myriad Genetics and Prism Ideas Ltd. Colin holds a medical degree from the University of London and is a Fellow of the Faculty of Pharmaceutical Medicine (UK).
GlyTherix CEO, Dr Brad Walsh stated, “Colin is a strong addition to the GlyTherix’s Clinical Advisory Board. He brings significant international radiopharmaceutical, medical, commercial and leadership experience gained from Telix and other pharmaceutical and specialty biotechnology companies. Colin has an extensive radiopharmaceutical experience and therapeutic background in oncology, including immuno-oncology, and a thorough understanding of the requisite steps involved in successfully taking early and late-stage cancer radiopharmaceutical drugs to market. Colin’s appointment adds to the international bench strength, in particular the current US-based clinical presence as we push our Glypican-1 pipeline towards Phase II clinical development.”
About GlyTherix
GlyTherix Ltd is an Australian immuno-oncology company specializing in developing targeted radiotherapies for solid tumors. Miltuximab® specifically targets GPC-1, a protein found in solid tumors such as prostate, bladder, pancreatic, glioblastoma, esophageal and ovarian cancers, and is not present in healthy tissue. The company has a strong proprietary and Intellectual Property position covering both Miltuximab® and the antigen GPC-1. This provides robust and long-term protection for the commercialization of important new treatments to people with little hope.
GlyTherix has completed a ‘First-in-Human’ trial of 12 patients using Miltuximab® with no drug-related adverse. Miltuximab® will be used in a Phase Ib/2 trial as an antibody theranostic. GlyTherix is interested in partnerships or collaborations with larger biotech and pharmaceutical partners.
For more Information regarding this release please contact:
GlyTherix: Dr Brad Walsh, CEO, +61 413 231 296 or brad.walsh@glytherix.com